You might also like
Alpha Cognition Inc. (ACI) is a biopharmaceutical company specializing in the research, development, and commercialization of treatments for neurological diseases. The company’s primary focus is on developing innovative pharmaceutical solutions for conditions such as Alzheimer’s disease and mild traumatic brain injury (mTBI). Its flagship product is ZUNVEYL oral tablets, which are FDA-approved for the treatment of mild-to-moderate Alzheimer’s disease.
- ZUNVEYL oral tablets - FDA-approved treatment for mild-to-moderate Alzheimer’s disease, currently in the early stages of commercialization.
- ALPHA-1062 - Product candidate under development for moderate-to-severe Alzheimer’s disease.
- ALPHA-1062IN - Product candidate targeting mild traumatic brain injury (mTBI).
- Preclinical Assets:
- ALPHA-0702 - Preclinical candidate aimed at treating neurodegenerative diseases, intended for out-licensing.
- ALPHA-0802 - Another preclinical candidate for neurodegenerative diseases, also planned for out-licensing.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Kenneth Cawkell ExecutiveBoard | CEO and Chairman | Director of Westmount Minerals Corp.; Director of Portofino Resources Inc.; Director of Centurion Minerals Inc.; Director of Well Health Technologies Corp. | Kenneth A. Cawkell is the CEO and Chairman of Alpha Cognition Inc. with over 30 years of experience as a biotech entrepreneur and general counsel, primarily responsible for the company’s de-risked drug development strategy. | View Report → |
Michael McFadden ExecutiveBoard | Chief Executive Officer | Advisory Board Member at MPower Health | Michael McFadden has served as the Chief Executive Officer of Alpha Cognition since April 12, 2021. He has also been a board member since March 28, 2021 and brings over 30 years of experience in biotech and pharmaceuticals. | |
Henry Du Executive | Vice President of Finance and Accounting | Henry Du is the Vice President of Finance and Accounting and interim Chief Financial Officer at ACOG since October 21, 2024. Previously, he held key financial roles at other companies. | ||
Lauren DAngelo Executive | Chief Operating Officer (COO) | Lauren D'Angelo is the Chief Operating Officer (COO) at ACOG since September 28, 2023. Previously, she served as the Chief Commercial Officer starting May 4, 2021. | ||
John Havens Board | Director | President of Seismic Exchange, Inc.; Vice Chairman/Board Member of the Houston Astros | John Havens serves as a Director and Chair of the Governance and Nomination Committee at ACOG as of at least March 31, 2025. He has extensive experience as an entrepreneur and investor, including his long tenure as President of Seismic Exchange, Inc. since 1978 and as Vice Chairman/Board Member of the Houston Astros. | |
Len Mertz Board | Chairman of the Board | Chairman of Shannon West Texas Memorial Hospital; Co-Founder and Partner at Mayne & Mertz, Inc.; Board Member at First National Bank of Mertzon; Chairman of PeraHealth | Len Mertz has been the Chairman of the Board at ACOG since March 18, 2021 and has been with the company since its founding, serving in multiple governance roles including Chair of the Audit Committee and member of the Governance and Nomination Committee. | |
Phillip Mertz Board | Director | Co-founder and Partner at Cenizas Capital; Initial Investor and Board Member at Secure Open Solutions; Co-founder at Py Square; Partner at Mertz Holdings | Phillip Mertz has been a Director at Alpha Cognition Inc. since March 18, 2021 and also serves as the Chair of the Compensation Committee at ACOG. He holds extensive experience in investment management, cybersecurity, and software development, including roles as Co-founder and Partner at Cenizas Capital and Initial Investor and Board Member at Secure Open Solutions. | |
Rajeev Rob Bakshi Board | Director | CEO of Active Witness Corp. | Rajeev 'Rob' Bakshi has been a Director at ACOG since November 15, 2017 and serves on both the Compensation and Audit Committees. He previously served as Chief Executive Officer during ACOG's qualifying transaction in March 2021. |
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
Branded competitors in the Alzheimer’s disease market include Namzaric®, which is produced by this company. | |
Corium | This company produces Adlarity®, a branded competitor in the Alzheimer’s disease market, and is also developing therapeutics for similar indications. |
This company is developing therapeutics for Alzheimer’s disease and is also conducting clinical trials for traumatic brain injury (TBI). | |
This company is developing therapeutics for Alzheimer’s disease. | |
Taurz | This company is developing therapeutics for Alzheimer’s disease. |
Vasopharm | This company is developing therapeutics for Alzheimer’s disease and is also conducting clinical trials for traumatic brain injury (TBI). |
Neuren Pharmaceuticals | This company is developing therapeutics for Alzheimer’s disease. |
Abliva | This company is developing therapeutics for Alzheimer’s disease. |
AB Science | This company is developing therapeutics for Alzheimer’s disease. |
SanBio/Sumitomo | This company is conducting clinical trials for traumatic brain injury (TBI). |
Otsuka/Avanir Pharmaceuticals | This company is conducting clinical trials for traumatic brain injury (TBI). |
Cellvation | This company is conducting clinical trials for traumatic brain injury (TBI). |
Eisai | This company markets Donepezil under the brand name Aricept, which is indicated for mild-to-moderate and moderate-to-severe stages of Alzheimer’s disease. |
This company co-markets Donepezil under the brand name Aricept, which is indicated for mild-to-moderate and moderate-to-severe stages of Alzheimer’s disease. | |
This company markets Rivastigmine capsules and patch under the brand name Exelon/Exelon Patch, which are indicated for mild-to-moderate and moderate-to-severe stages of Alzheimer’s disease. | |
Janssen | This company markets Galantamine under the brand names Reminyl and Razadyne/Razadyn ER, which are indicated for mild-to-moderate stages of Alzheimer’s disease. |
Recent press releases and 8-K filings for ACOG.
- FDA Approval: Alpha Cognition's oral therapy, ZUNVEYL (benzgalantamine), has received FDA approval for treating mild to moderate Alzheimer's disease, offering a dual mechanism intended to improve gastrointestinal tolerability.
- Strategic Market Focus: The presentation highlights a targeted commercialization strategy in the Long Term Care segment, emphasizing unmet market needs and outlining upcoming catalysts, including additional formulation and pipeline developments.
- Alpha Cognition Inc. provided an investor update emphasizing its FDA-approved oral therapy, ZUNVEYL, for treating mild to moderate Alzheimer’s dementia.
- The update detailed a strategic commercial launch focused on the long-term care (LTC) market with plans to achieve breakeven in 3 years and address limitations of current AD treatments.
- It also outlined forward-looking pipeline milestones including clinical studies, reformulation projects, and expansion into new therapeutic areas.